Page 99 - Revista 2019

Cáncer colorrectal, tamizaje molecular para agregación familiar. Bohórquez et al.

78. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B. (2006) BRAF mutations are
associated with distinctive clinical, pathological and molecular features of colorectal cancer indepen-
dently of microsatellite instability status. Mol Cancer. 5:2.
79. Lubomierski N, Plotz G, Wormek M, Engels K, Kriener S, Trojan J, et al. (2005) BRAF mutations in
colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer. 104(5):952-61.
80. Marzouk O, Schofi eld J. (2011) Review of histopathological and molecular prognostic features in co-
lorectal cancer. Cancers. 3(2):2767-810.
81. Sayagues JM, Del Carmen S, Del Mar Abad M, Corchete LA, Bengoechea O, Anduaga MF, et al.
(2018) Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic
colorectal cancer patients. Oncotarget. 9(35):24081-96.
82. D’Haene N, Fontanges Q, De Neve N, Blanchard O, Melendez B, Delos M, et al. (2018) Clinical appli-
cation of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian
experience. Oncotarget. 9(29):20761-8.
83. Koinuma K, Shitoh K, Miyakura Y, Furukawa T, Yamashita Y, Ota J, et al. (2004) Mutations of BRAF
are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J
cancer 108(2):237-42.
84. Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY. (2015) KRAS and BRAF gene mutations and DNA
mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol. 21(5):1595-
605.
85. Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, et al. (2012) KRAS, BRAF and PIK3CA mutations
and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One. 7(5): e36653.
86. Shen H, Yuan Y, Hu HG, Zhong X, Ye XX, Li MD, et al. (2011) Clinical signifi cance of K-ras and
BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol. 17(6):809-16.
87. Naguib A, Mitrou PN, Gay LJ, Cooke JC, Luben RN, Ball RY, et al. (2010) Dietary, lifestyle and
clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of
colorectal cancers in the EPIC Norfolk study. BMC Cancer. 10:99.
88. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. (2010) Clinicopathological and protein cha-
racterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J
Cancer. 127(2):367-80.
89. Shaukat A, Arain M, Thaygarajan B, Bond JH, Sawhney M. (2010) Is BRAF mutation associated with
interval colorectal cancers? Dig Dis Sci. 55(8):2352-6.
90. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. (2009) KRAS codon 61,
146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13
wild-type metastatic colorectal cancer. Br J Cancer. 101(4):715-21.
91. Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE, Passarelli MN, et al. (2012)
BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor
characteristics. Cancer Epidemiol Biomarkers Prev. 21(10):1792-8.
92. Rozek LS, Herron CM, Greenson JK, Moreno V, Capella G, Rennert G, et al. (2010) Smoking, gender,
and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers
Prev. 19(3):838-43.
93. Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, et al. (2015) Molecular
markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology
148(1):88-99.
94. Thiel A, Ristimaki A. (2013) Toward a molecular classifi cation of colorectal cancer: The role of BRAF.
Front Oncol 3:281.
95. Wangefjord S, Sundstrom M, Zendehrokh N, Lindquist KE, Nodin B, Jirstrom K, et al. (2013) Sex di-
fferences in the prognostic signifi cance of KRAS codons 12 and 13, and BRAF mutations in colorectal
cancer: a cohort study. Biol Sex Differ. 4(1):17.

99
Rev. Asoc. Col. Cienc.(Col.), 2019; 31: 87-99